Imunon(NASDAQ) IMNN

Current Price$1.65

Market Cap$7.44M

Since IPO (1995)-100%

5 Year-99%

1 Year-75%

1 Month-3%

Imunon last closing stock price
Metric	Price	Date
Last close	USD 1.77	2026-07-20

Imunon stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-9.69%	USD 1.96	2026-07-13
1 month	-2.75%	USD 1.82	2026-06-18
3 month	-41.39%	USD 3.02	2026-04-21
Year to date	-53.54%	USD 3.81	2025-12-31
1 year	-75.42%	USD 7.20	2025-07-18
3 year	-88.97%	USD 16.04	2023-07-21
5 year	-99.2%	USD 221.09	2021-07-21
Since inception	-100%	USD 225,327.24	1995-07-24

Imunon Financials at a Glance

Market Cap

$7.44M

Revenue (TTM)

$0.00

Net Income (TTM)

-$14.64M

EPS (TTM)

-$5.17

P/E Ratio

-0.34

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$1.65

Volume

3,363,229.87

Open

$1.81

Price

$1.65

Volume

3,363,229.87

Open

$1.81

Previous Close

$1.77

Daily Range

$1.59 - $2.00

52-Week Range

$1.59 - $8.19

Estimated Earnings Date

Aug 4, 2026

Dividend

$0.00

Beta (Volatility)

0.79 (Low)

Price

$1.65

Volume

3,363,229.87

Open

$1.81

Previous Close

$1.77

Daily Range

$1.59 - $2.00

52-Week Range

$1.59 - $8.19

Estimated Earnings Date

Aug 4, 2026

IMNN News

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Imunon

Imunon develops new treatments for cancer and infectious diseases. Its therapies aim to help patients with ovarian cancer and those needing vaccines. The company focuses on DNA-based medicines that target disease at the source.

Products and Services

GEN-1 Immunotherapy: DNA-based treatment for ovarian cancer, delivers immune-boosting proteins directly to tumors. (0% of revenue; no product sales)
ThermoDox: Heat-activated chemotherapy using a special capsule to release medicine at tumor sites. (0% of revenue; no product sales)
PlaCCine Vaccine Platform: DNA vaccine technology for infectious diseases, including a COVID-19 booster. (0% of revenue; no product sales)
Feasibility Platforms: Early-stage research for new DNA and RNA therapies against cancer and infections. (0% of revenue; no product sales)

Growth and Expansion

Advanced GEN-1 to Phase III clinical trials for ovarian cancer in 2025.
Completed Phase I trial for COVID-19 booster vaccine in 2025.
Partnered with Break Through Cancer Foundation for combination therapy studies in 2025.
Changed name from Celsion to Imunon in September 2022 to reflect new focus.

What Makes Imunon Stand Out

Imunon uses non-viral DNA technology, which may allow safer and repeatable treatments. Its vaccine platform is designed for quick adaptation to new diseases and easy storage. The company operates its own clinical manufacturing facility, supporting in-house development.

Five Things You Need to Know

No product revenue as of December 2025; relies on capital raises.
Net loss was $14.5 million in 2025, down 22.1% from 2024.
Research and development expenses fell 33.1% to $7.8 million in 2025.
Cash and cash equivalents were $8 million at end of 2025, down 48.9% year-on-year.
Management has raised concerns about the company’s ability to continue without new funding.

Bottom Line

Imunon has shifted from research to late-stage clinical trials, focusing on DNA-based therapies. The company faces ongoing financial challenges but continues to develop new treatments for cancer and infectious diseases.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Stacy R. Lindborg, PhD

Website

imunon.com

Headquarters

Lawrenceville, NJ 08648, US

IMNN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-341.23%

Return on Capital

-181.55%

Return on Assets

-182.59%

Earnings Yield

-2.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.44M

Shares Outstanding

4.20M

Volume

3.36M

Avg. Volume

51.71K

Financials (TTM)

Gross Profit

-$331.22K

Operating Income

-$14.81M

EBITDA

-$13.97M

Operating Cash Flow

-$15.03M

Capital Expenditure

-$20.92K

Free Cash Flow

-$15.06M

Cash & ST Invst.

$4.79M

Total Debt

$911.75K

Imunon Performance Analysis

Imunon annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 500,000	0.0%
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Imunon sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Imunon annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -65.55	-91.2%
2023	2023-12-31	USD -28.14	-57.1%
2024	2024-12-31	USD -21.10	-25.0%
2025	2025-12-31	USD -6.83	-67.7%

Imunon sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	49.2%
Q3	2025-09-30	38.0%
Q4	2025-12-31	-71.6%
Q1	2026-03-31	57.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$166.54K

+92.3%

Gross Margin

0.00%

N/A

Market Cap

$7.44M

N/A

Market Cap/Employee

$371.89K

N/A

Employees

N/A

Net Income

-$4.25M

-3.6%

EBITDA

-$4.08M

-1.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$4.79M

+66.9%

Total Debt

$911.75K

-9.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$492.85K

-19.6%

Short Term Debt

$418.90K

+6.1%

Return on Assets

-1.83%

N/A

Return on Invested Capital

-3.84%

N/A

Free Cash Flow

-$3.99M

-28.3%

Operating Cash Flow

-$3.99M

-40.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BOLTBolt Biotherapeutics, Inc.

BOLTBolt Biotherapeutics, Inc.$4.29-4.13%

CLRBCellectar Biosciences, Inc.

CLRBCellectar Biosciences, Inc.$2.63+4.27%

TRAWTraws Pharma, Inc.

TRAWTraws Pharma, Inc.$0.62+0.70%

COCPCocrystal Pharma, Inc.

COCPCocrystal Pharma, Inc.$0.94+1.34%

EVGNEvogene Ltd.

EVGNEvogene Ltd.$0.53-2.78%

DWTXDogwood Therapeutics, Inc.

DWTXDogwood Therapeutics, Inc.$1.43+3.62%

MRKRMarker Therapeutics, Inc.

MRKRMarker Therapeutics, Inc.$1.32+2.73%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

VIVKVivakor

VIVKVivakor$5.49+2.17%

UTZUtz Brands

UTZUtz Brands$14.12+0.89%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.28+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.44+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.37+0.06%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$34.83+0.23%

CONLGraniteShares ETF Trust - GraniteShares 2x Long Coin Daily ETF

CONLGraniteShares ETF Trust - GraniteShares 2x Long Coin Daily ETF$6.25+0.25%

Questions About IMNN

What is the current price of Imunon?

Imunon is trading at $1.65 per share.

What is the 52-week range for Imunon?

Over the past 52 weeks, Imunon has traded between $1.59 and $8.19.

How much debt does Imunon have?

As of the most recent reporting period, Imunon reported total debt of $911.75K.

How much cash does Imunon have on hand?

Imunon reported $4.79M in cash and cash equivalents in its most recent financial results.

What is Imunon’s dividend yield?

Imunon does not currently have a dividend yield.

Imunon(NASDAQ) IMNN

Imunon Financials at a Glance

IMNN News

3 Biotech Stocks To Avoid

A Fool Looks Back

The Fool Looks Ahead

This Week in Biotech

3 Horrendous Health-Care Stocks This Week

Why Celsion Shares Were Eviscerated

Why Shares of Celsion Got Crushed Today

Celsion Collapses on Failure: What's Next?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Imunon

Products and Services

Growth and Expansion

What Makes Imunon Stand Out

Five Things You Need to Know

Bottom Line

IMNN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Imunon Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IMNN

What is the current price of Imunon?

What is the 52-week range for Imunon?

How much debt does Imunon have?

How much cash does Imunon have on hand?

What is Imunon’s dividend yield?

Premium Investing Services